Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas
The purpose of this study is to determine whether combining of Temozolomide and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with Advanced Malignant Gliomas. The effectiveness and safety of CIK cells for the treatment of Malignant Glioma is also evaluated.
Cytokine-Induced Killer Cells|Advanced Milignant Gliomas
DRUG: Temozolomide|BIOLOGICAL: CIK
Overall survival, 5 years
Adverse events, 4 weeks
The purpose of this study is to determine whether combining of Temozolomide and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with Advanced Malignant Gliomas. The effectiveness and safety of CIK cells for the treatment of Malignant Glioma is also evaluated.